ProCE Banner Activity

ALTAMIRA: Phase II Trial of Acalabrutinib + Rituximab as First-line Treatment for Mantle Cell Lymphoma in Patients Aged ≥60 Yr

Conference Coverage
Slideset

In ALTAMIRA, acalabrutinib plus rituximab was a safe and effective for treatment of older patients with low-risk MCL.

Released: December 12, 2024

Expiration: December 11, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation